Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Kerry Rogers
- Target Recruit Count
- 87
- Registration Number
- NCT02427451
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 131
- Registration Number
- NCT02427620
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02420912
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- Jason Robert Gotlib
- Target Recruit Count
- 4
- Registration Number
- NCT02415608
- Locations
- 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 47
- Registration Number
- NCT02406742
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇦🇹University Hospital of Salzburg St Johanns Spital, Salzburg, Austria
🇺🇸The West Clinic, Memphis, Tennessee, United States
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 124
- Registration Number
- NCT02403271
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 61
- Registration Number
- NCT02401048
- Locations
- 🇺🇸
Site-0343, Hackensack, New Jersey, United States
🇺🇸Site-0397, Birmingham, Alabama, United States
🇺🇸Site-0047, Duarte, California, United States
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02381080
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 58
- Registration Number
- NCT02356458
- Locations
- 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇮🇹European Institute of Oncology, Milano, Italy
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02352558
- Locations
- 🇺🇸
Virginia Oncology Associates, Norfolk, Virginia, United States
🇺🇸West Clinic, Germantown, Tennessee, United States
🇺🇸Northwest Cancer Specialists, PC, Vancouver, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.